日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cancer Survival at a Comprehensive Cancer Center Compared with Surveillance, Epidemiology, and End Results (SEER) Estimates

综合癌症中心癌症生存率与监测、流行病学和最终结果 (SEER) 估计值的比较

Salgia, Ravi; Alvarnas, Joseph; Trisal, Vijay; Vanderplas, Ann; Li, Xiaochen; Arias-Romero, Javier; Fricke, Jeremy; Frankel, Paul; Mambetsariev, Isa; Rice, Hannah; Levine, Harlan; van den Brink, Marcel R M

Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial

HIV相关淋巴瘤患者自体造血干细胞移植后的免疫恢复情况(BMT CTN 0803/AMC 071试验)

Shindiapina, Polina; Pietrzak, Maciej; Seweryn, Michal; McLaughlin, Eric; Zhang, Xiaoli; Makowski, Mat; Ahmed, Elshafa Hassan; Schlotter, Sarah; Pearson, Rebecca; Kitzler, Rhonda; Mozhenkova, Anna; Le-Rademacher, Jennifer; Little, Richard F; Akpek, Gorgun; Ayala, Ernesto; Devine, Steven M; Kaplan, Lawrence D; Noy, Ariela; Popat, Uday R; Hsu, Jack W; Morris, Lawrence E; Mendizabal, Adam M; Krishnan, Amrita; Wachsman, William; Williams, Nita; Sharma, Nidhi; Hofmeister, Craig C; Forman, Stephen J; Navarro, Willis H; Alvarnas, Joseph C; Ambinder, Richard F; Lozanski, Gerard; Baiocchi, Robert A

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

对于接受异基因造血干细胞移植的70岁以上血液系统恶性肿瘤患者,以美法仑为基础的减低强度预处理方案可带来良好的疾病控制效果和可接受的毒性反应。

Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun; Armenian, Saro; Dadwal, Sanjeet; Salman, Jaroslava; Mokhtari, Sally; Cao, Thai; Sandhu, Karamjeet; Rouse, Michelle; Mei, Matthew; Ali, Haris; Parker, Pablo; Alvarnas, Joseph; Smith, Eileen; Donnell, Margaret O; Marcucci, Guido; Snyder, David; Nademanee, Auayporn; Forman, Stephen J; Stein, Anthony; Nakamura, Ryotaro

Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis

采用他克莫司/西罗莫司为基础的GVHD预防方案,降低MDS的异基因造血干细胞移植强度

Nakamura, Ryotaro; Palmer, Joycelynne M; O'Donnell, Margaret R; Stiller, Tracey; Thomas, Sandra H; Chao, Joseph; Alvarnas, Joseph; Parker, Pablo M; Pullarkat, Vinod; Maegawa, Rodrigo; Stein, Anthony S; Snyder, David S; Bhatia, Ravi; Chang, Karen; Wang, Shirong; Cai, Ji-Lian; Senitzer, David; Forman, Stephen J

Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia

一项针对高危白血病患者的异基因造血干细胞移植强化预处理方案的二期临床试验

Stein, A S; O'Donnell, M R; Synold, T W; Dagis, A C; Tsirunyan, A; Nademanee, A P; Parker, P M; Pullarkat, V A; Snyder, D S; Spielberger, R T; Wong, J Y C; Alvarnas, J C; Thomas, S H; Forman, S J

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma

使用慢病毒载体修饰的 CD34(+) 细胞对接受移植的艾滋病相关淋巴瘤患者进行基于 RNA 的 HIV 基因治疗

David L DiGiusto, Amrita Krishnan, Lijing Li, Haitang Li, Shirley Li, Anitha Rao, Shu Mi, Priscilla Yam, Sherri Stinson, Michael Kalos, Joseph Alvarnas, Simon F Lacey, Jiing-Kuan Yee, Mingjie Li, Larry Couture, David Hsu, Stephen J Forman, John J Rossi, John A Zaia